JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2005, 54(5):207-210

Ouabain: from an Arrow Poison to a New Steroidal Hormone

P. Mučaji, M. Nagy, D. Grančai
Farmaceutická fakulta Univerzity Komenského v Bratislavě, Katedra farmakognózie a botaniky, SR

For more than 200 years, cardiotonic glycosides have been used for the treatment of congestive heart failure. Ouabain is a well-known arrow poison obtained from different Acokanthera or Strophanthus species. Much information has now accumulated that this plant toxin and its congeners are mammalian steroid hormones involved in the pathophysiology of cardiovascular diseases. There is an interesting fact that 50% patients with essential hypertension have elevated levels of endogenous ouabain. A better knowledge of the interactions of these compounds with the hormones of salt and water metabolism might help to improve the diagnosis and therapy of hypertension.

Keywords: ouabain; cardioglycosides; steroid hormones

Received: February 18, 2005; Accepted: April 10, 2005; Published: May 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mučaji P, Nagy M, Grančai D. Ouabain: from an Arrow Poison to a New Steroidal Hormone. Čes. slov. farm. 2005;54(5):207-210.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Neuwinger, H. D.: African Ethnobotany. Poisons and Drugs. Chemistry, Pharmacology, Toxicology. Chapman & Hall GmbH, Weinheim, Germany, 1996.
    2. Huang, Y. T., Chueh, S. Ch., Teng, Ch. M., Guh, J. H.: Biochemical Pharmacology, 2004; 67, 727-733. Go to original source... Go to PubMed...
    3. Slovenský liekopis, vydanie prvé, zväzok V. Ministerstvo zdravotníctva Slovenskej republiky, vydavateľstvo Herba, 2002, s.3253.
    4. European Pharmacopoeia, Fifth Edition, Vol.2, Council of Europe, Strasbourg, 01/2005, s. 2158.
    5. Juhaszova, M., Blaustein, P. M.: Proc. Natl. Acad. Sci. USA, 1997; 94, 1800-1805. Go to original source... Go to PubMed...
    6. Blaustein, M. P., Robinson, S. W., Gottlieb, S. S. et al.: Molecular Interventions, 2003; 3, 68-72. Go to original source... Go to PubMed...
    7. Aizman, O., Uhlén, P., Lal, M. et al.: PNAS, 2001; 98, 13420-13424.
    8. Paula, S., Tabet, M.R., Ball, W.J.: Biochemistry, 2005; 44, 498-510. Go to original source... Go to PubMed...
    9. Schoner, W.: Eur. J. Biochem., 2002; 269, 2440-2448. Go to original source... Go to PubMed...
    10. Nakanishi, K., Berova, N., Lo, L.Ch. et al.: Searching for an endogenous mammalian cardiotonic factor. In: Saponins used in Traditional and Modern Medicine (Eds.: Waller, G. R.,Yamasaki, K.), New York, Plenum Press, 1996, s. 219-224. Go to original source...
    11. Qazzaz, H. M., Cao, Z., Bolanowski, D. D. et al.: Clinical Chemistry, 2004; 50, 612-620. Go to original source... Go to PubMed...
    12. Wang, J. G., Staessen, J. A., Messaggio, E. et al.: J. Hypertens., 2003; 21, 1475-1481. Go to original source... Go to PubMed...
    13. Wang, H., Leenen, F. H.: J. Hypertens., 2003; 21, 1519-1524. Go to original source... Go to PubMed...
    14. Foster, R. H., Prat, H., Rothman, I.: Gen. Pharmac., 1998; 31, 499-501. Go to original source... Go to PubMed...
    15. Gooz, M., Toth, M., Vakkuri, O. et al.: Life Sciences, 2004; 74, s. 2111- 2128. Go to original source... Go to PubMed...
    16. Wang, H., Huang, B. S., Leenen, F. H. H.: Am. J. Physiol. Heart Circ. Physiol., 2003; 285, 2516-2523. Go to original source... Go to PubMed...
    17. Schoner, W.: Exp. Clin. Endocrinol. Diabetes, 2000; 108, 449-454. Go to original source... Go to PubMed...
    18. Balzan, S., Nicolini, G., Bellitto, L. et al.: J. Cardiovasc. Pharmacol., 2003; 42, 32-36. Go to original source... Go to PubMed...
    19. Kurup, R. K., Kurup, P. A.: Intern. J. Neuroscience., 2003; 113, 1427-1443. Go to original source... Go to PubMed...
    20. Kurup, R. K., Kurup, P. A.: Intern. J. Neuroscience., 2003; 113, 1395-1412. Go to original source... Go to PubMed...
    21. Martinka, E., Matúšek, J., Očenášová, A. et al.: Bratisl. lek. Listy, 1997; 98, 544-554.

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.